Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Amino Acids, Peptides, and Proteins
Peptides
Clear Filters

Search Clinical Trials

16 Results
Completed
Lantus in the Treatment of Type 1 Diabetes Children
The landmark report of the diabetes control and complications trial (DCCT) trial has shown that intensive management delays and/or prevents complications in small vessels associated with Type 1 diabetes (T1DM). …
Baylor Role: Lead Sponsor
Completed
The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes
The Diabetes Control and Complications Trial (DCCT) showed that improving blood sugar control for individuals with Type 1 diabetes (T1DM) stopped or delayed the onset of long-term complications. As a …
Baylor Role: Lead Sponsor
Completed
The Role of Amylin and Glucagon in T1DM
Objective: To develop a new treatment approach in the prevention of hypo and hyperglycemia in children with type 1diabetes. Background/Rationale: The diabetes control and complications trial (DCCT) showed that improving …
Baylor Role: Lead Sponsor
Unknown Status
Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion
PROTOCOL OUTLINE: Patients are assigned to one of 6 study groups. Patients receive infusions of stable isotope tracers: [15N]urea IV beginning at -12 hours and continuing over 22 hours to …
Baylor Role: Collaborator
Completed
Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism
PROTOCOL OUTLINE: This is a randomized study. Patients are randomly assigned to a 6-month course of leuprolide versus ethinyl estradiol/norethindrone (Ovcon 35) versus leuprolide plus Ovcon 35. Leuprolide is administered …
Baylor Role: Collaborator
Completed
Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome
PROTOCOL OUTLINE: Participants are treated with subcutaneous leuprolide acetate followed by oral spironolactone. Each treatment is administered daily for 6 weeks, with a 6-week washout between drugs. Patients and controls …
Baylor Role: Collaborator